How daraxonrasib impacted one pancreatic cancer patient| STAT (opens in a new tab)

statnews.com · 2026-10-23

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

17 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail

The story

How daraxonrasib impacted one pancreatic cancer patient| STAT

statnews.com · 2026-10-23

The story’s checkable claims.

Read the original story

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Reading mode

Scan verdicts. Open evidence only when needed.

Claim 1 of 4Not checkedThe approval of daraxonrasib is described as the biggest advance in decades against pancreatic cancer.View evidenceHide evidence

As statedthe biggest advance in decades

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 4Not checkedThe story says data readouts do not show what the extra months of life mean to patients and loved ones, or the resources required to access new medicines.View evidenceHide evidence

As statedextra months

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 4Not checkedDana Senaha told the story of her husband Bobby Senaha’s experience participating in the daraxonrasib clinical trial after his cancer stopped responding to standard chemotherapy.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 4Not checkedThe family pursued treatment in California, then Texas, and then returned home to Hawaii, where Bobby Senaha died on Aug. 25, 2024.View evidenceHide evidence

As statedAug. 25, 2024

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results